Afficher la notice abrégée

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic

hal.structure.identifierCentre population et développement [CEPED - UMR_D 196]
dc.contributor.authorSCHULTZ, Émilien
hal.structure.identifierCentre Émile Durkheim [CED]
dc.contributor.authorMIGNOT, Léo
hal.structure.identifierVecteurs - Infections tropicales et méditerranéennes [VITROME]
hal.structure.identifierCERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société [CERMES3 - UMR 8211 / U988 / UM 7]
dc.contributor.authorWARD, Jeremy
hal.structure.identifierCentre Émile Durkheim [CED]
dc.contributor.authorBOAVENTURA BOMFIM, Daniela
hal.structure.identifierInstitut Paoli-Calmettes [IPC]
hal.structure.identifierCentre d'Investigations Cliniques en Biothérapies [Marseille]
hal.structure.identifierCentre de Recherche en Cancérologie de Marseille [CRCM]
dc.contributor.authorCHABANNON, Christian
hal.structure.identifier“Cancer, Biomedicine & Society” group [SESSTIM - U1252 INSERM - AMU - UMR 259 IRD]
hal.structure.identifierBiostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] [BiosTIC ]
dc.contributor.authorMANCINI, Julien
dc.date.issued2022-12
dc.identifier.issn0040-5957
dc.description.abstractEnObjectives: During the coronavirus disease 2019 (COVID-19) pandemic, public debates overtly addressed the promises of new innovative drugs. Many of these debates pitted those who advocated for the development of new drugs by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development.Methods: Data were collected in January 2021 from a quota sample of the French population aged 18-75years (n=1,000) during the second round of the "Health Literacy Survey 2019" (HLS19).Results: We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the navigational health literacy score, OR 3.34 [2.13-5.24]). Respondents with a low level of trust in pharmaceutical companies or politicians were two times less likely to agree that new drugs are always more effective than old ones (OR 0.63 [0.42-0.95] and OR 0.68 [0.49-0.94], respectively). A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry.Conclusion: Our study shows that the perceived effectiveness of innovative drugs is associated with familiarity with the health care system and trust in institutions.
dc.language.isoen
dc.publisherElsevier Masson
dc.subject.enCOVID-19
dc.subject.enDrug innovation
dc.subject.enPublic attitude
dc.subject.enSocial pharmacology
dc.subject.enSociology
dc.title.enPublic perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic
dc.typeArticle de revue
dc.identifier.doi10.1016/j.therap.2022.05.001
dc.subject.halSciences de l'Homme et Société/Sociologie
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Médicaments
bordeaux.journalTherapies
bordeaux.page693-701
bordeaux.volume77
bordeaux.issue6
bordeaux.peerReviewedoui
hal.identifierhal-03676822
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-03676822v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Therapies&rft.date=2022-12&rft.volume=77&rft.issue=6&rft.spage=693-701&rft.epage=693-701&rft.eissn=0040-5957&rft.issn=0040-5957&rft.au=SCHULTZ,%20%C3%89milien&MIGNOT,%20L%C3%A9o&WARD,%20Jeremy&BOAVENTURA%20BOMFIM,%20Daniela&CHABANNON,%20Christian&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée